Categories: Clinical TrialNews

1nHealth launches new site featuring 1nData study platform and real-world case study library

ORLANDO, Fla., March 11, 2025 /PRNewswire/ — In an industry where enrollment delays and inefficiencies are the norm, 1nHealth is resetting the standard by fully owning enrollment. With the launch of its newly redesigned website, 1nHealth is giving sponsors and site teams an inside look at the strategies, technology, and results that drive its industry-leading patient enrollment efforts.

A major highlight of the new site is 1nData, the company’s all-in-one centralized study data hub that allows for patient tracking across multiple sites, instantaneous follow-up patient communication for site staff, and a customizable data dashboard tailored to each study’s needs. 1nData ensures that sponsors and sites can see exactly what’s happening with their enrollment efforts at any time.

“1nData is the platform from which we have built a successful enterprise,” said Dan Brenner, CEO of 1nHealth. “A centralized data hub gives sponsors and site teams the ability to track enrollment, automate touchpoints, and make informed decisions in real time. Beyond a single source of truth, 1nData is the nucleus of our strong track record of performance. We’re excited to highlight 1nData online and across our collaborations with Partners. 1nData at the center of enrollment means fewer delays, better patient retention, and ultimately, faster trial completion.”

Additionally, the site now features an expanded case study library, covering various therapeutic areas. From success in oncological and neurological trials to rare diseases and infectious diseases, sponsors can explore real-world examples of how 1nHealth has consistently exceeded recruitment targets.

“The biggest challenge in clinical trial enrollment isn’t just finding patients – it’s understanding how to engage them effectively,” said Kayt Leonard, CCO of 1nHealth. “With expanded case studies and unique industry perspectives, we’re not just telling sponsors that we get results—we’re laying out the evidence of what 1nHealth delivers: real, proven outcomes.”

The new website is now live at www.1nhealth.com, offering a streamlined experience for sponsors, CROs, and site teams looking to optimize patient enrollment and retention.

About 1nHealth
From kick-off to last patient in, 1nHealth builds a reliable source of referred enrollments through proven recruitment programs and high-touch patient engagement. With over 30,000 patients enrolled across more than 100 studies, 1nHealth helps study sponsors and clinical research organizations overcome enrollment challenges, connect diverse patient populations to clinical studies, and improve trial outcomes. 

Contact Information:
1nHealth
Ryan Day
904.534.1608
ryan.day@1nHealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/1nhealth-launches-new-site-featuring-1ndata-study-platform-and-real-world-case-study-library-302398680.html

SOURCE 1nHealth

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

20 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

20 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

20 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

20 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

20 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

20 hours ago